Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00460707 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety and Interaction Between Casopitant and Ketoconazole When Taken By Healthy Adults
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 85
- Enrollment target
NCT00460707 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 85 participants.
The verdict
NCT00460707, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 85 participants
- Enrollment target
Study Summary
Casopitant may affect liver enzymes that metabolize ketoconazole. This study is designed to test the safety and the extent of the Casopitant affect on ketoconazole levels in healthy human subjects.
Interventions
- DRUG Ketoconazole
- DRUG Casopitant 50 mg
- DRUG Casopitant 150 mg
- DRUG Casopitant 150 mg matching placebo
- DRUG Casopitant 50 mg matching placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2007-04-16 |
| Est. Completion | 2007-08-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00460707
The ClinicalTrials.gov registry entry for NCT00460707 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Ketoconazole is the first listed.
NCT00460707 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00460707 about?
NCT00460707 is a clinical study titled "A Study to Assess the Safety and Interaction Between Casopitant and Ketoconazole When Taken By Healthy Adults". Casopitant may affect liver enzymes that metabolize ketoconazole. This study is designed to test the safety and the extent of the Casopitant affect on ketoconazole levels in healthy human subjects.
What is the current status of trial NCT00460707?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 85 participants. The study started on 2007-04-16. Estimated completion is 2007-08-27.
What interventions are being tested in trial NCT00460707?
The interventions under investigation include: Ketoconazole (DRUG), Casopitant 50 mg (DRUG), Casopitant 150 mg (DRUG), Casopitant 150 mg matching placebo (DRUG), Casopitant 50 mg matching placebo (DRUG).
Who is sponsoring clinical trial NCT00460707?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.